CRISPR Therapeutics
CRSP
CRSP
445 hedge funds and large institutions have $3.47B invested in CRISPR Therapeutics in 2022 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 170 increasing their positions, 97 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding
Funds holding: 445 → 445 (0)
4% less call options, than puts
Call options by funds: $149M | Put options by funds: $156M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
445
Holding in Top 10
3
Calls
$149M
Puts
$156M
Top Buyers
| 1 | +$290M | |
| 2 | +$63.2M | |
| 3 | +$55.9M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.5M |
Top Sellers
| 1 | -$81.7M | |
| 2 | -$31.9M | |
| 3 | -$31M | |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$28.5M |
| 5 |
Millennium Management
New York
|
-$21.3M |